Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy

BACKGROUND: Lipegfilgrastim is a novel glyco-pegylated granulocyte-colony stimulating factor in development for neutropenia prophylaxis in cancer patients receiving chemotherapy. This phase III, double-blind, randomized, active-controlled, noninferiority trial compared the efficacy and safety of lip...

Descripción completa

Detalles Bibliográficos
Autores principales: Bondarenko, Igor, Gladkov, Oleg A, Elsaesser, Reiner, Buchner, Anton, Bias, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751756/
https://www.ncbi.nlm.nih.gov/pubmed/23945072
http://dx.doi.org/10.1186/1471-2407-13-386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751756/
https://www.ncbi.nlm.nih.gov/pubmed/23945072
http://dx.doi.org/10.1186/1471-2407-13-386

Ejemplares similares